IonQ's stock has been on a wild ride the past several months. The company is seeing strong growth and recently made two acquisitions. The stock is pricey, and it's a very speculative investment ...

The egg shortage and its effect on prices aren't doing the company any favors. It recently imposed surcharges on the many meals it makes with the protein, but these levies aren't universal. For ...

The S&P 500 tumbled 1.8% to resume its slide after a mini-recovery from the prior day clawed back some of its sharp drop over recent weeks. The Dow Jones Industrial Average dropped 427 points ...

After soaring following the election, Tesla (NASDAQ: TSLA) stock ran into a wall in February as a number of news items, macro challenges, and CEO Elon Musk's involvement in the Department of ...

De Beers and Botswana have also formalised a 25-year extension of the mining licenses for Debswana, a 50/50 joint venture that operates the Jwaneng and Orapa mines. Under the new deal, the share of ...

Shares of online learning platform company Nerdy (NYSE: NRDY) fell hard today after the company reported its fourth-quarter results yesterday. While sales and earnings beat Wall Street's consensus ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Bitcoin has fallen below $90,000 for the first time this year, triggering a widespread sell-off in the crypto market while the U.S. remains asleep. At 4 a.m. ET, Bitcoin’s decline dragged the ...

An icon in the shape of a lightning bolt. Impact Link Tesla sales in Europe plunged in January, falling 45% compared with the same month last year, while overall sales of electric vehicles ...

Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections ...

Hims & Hers (NYSE:HIMS) stock tumbled 20% in post-market trading Monday after the company released its Q4 earnings report and 2025 guidance amid a possible FDA crackdown on its GLP-1 weight-loss ...